Annals of Clinical Psychiatry, published by QUADRANT HEALTHCOM INC, is a leading journal in the fields of Medicine and Psychiatry & Mental Health. With its longstanding commitment to advancing clinical knowledge since 1989, this esteemed journal contributes invaluable insights into current psychiatric practices and mental health research. The journal is recognized in the Scopus ranking with a position in the 34th percentile, reflective of its focused scope and substantial academic contributions. While access to the journal is tailored for professionals and researchers, the absence of Open Access highlights the journal's dedication to maintaining quality and rigorous peer-reviewed standards. As part of the Q3 quartile for both Medicine and Psychiatry categories in 2023, Annals of Clinical Psychiatry serves as an essential resource for those dedicated to improving mental health outcomes, making it a vital platform for practitioners, researchers, and students alike. Situated in Parsippany, New Jersey, the journal remains a pivotal entity that fosters scholarly dialogue and exploration in clinical psychiatry.

Journal of Psychopathology, published by PACINI EDITORE, is a pivotal academic resource in the realms of clinical psychology and psychiatry. With an ISSN of 1592-1107 for print and 2499-6904 for electronic formats, this journal has been a significant platform for scholarly discourse since its inception in 2001, continuing through to 2024. Situated in Pisa, Italy, it is recognized for its rigorous academic standards, as evidenced by its Q3 ranking in both Clinical Psychology and Psychiatry and Mental Health categories as of 2023. The journal focuses on publishing high-quality research articles, reviews, and case studies that contribute to a comprehensive understanding of psychopathological issues. Although not open access, the journal promotes accessibility through various institutional subscriptions, ensuring wide dissemination of valuable insights. With significant Scopus rankings—177 out of 311 in Clinical Psychology and 360 out of 567 in Psychiatry and Mental Health—the journal is essential for researchers, practitioners, and students dedicated to advancing knowledge and practices in mental health.

The Journal of Affective Disorders is a premier publication in the field of Clinical Psychology and Psychiatry and Mental Health, published by Elsevier. With an impressive impact factor and a consistent ranking in the Q1 category—12th in Clinical Psychology and 40th in Psychiatry and Mental Health—the journal serves as a critical platform for advancing research on affective disorders since its inception in 1979. The journal’s scope encompasses a wide range of topics related to mood disorders, providing researchers, professionals, and students with the latest findings, theoretical developments, and clinical insights. Despite being a non-open-access journal, subscribers benefit from comprehensive access to high-quality, peer-reviewed articles that inform clinical practice and enrich academic discourse. With its commitment to fostering scientific progress, The Journal of Affective Disorders remains instrumental in shaping the future of mental health research and practice.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

NERVENARZT, published by Springer, has established itself as a significant platform in the fields of Medicine, Neurology, and Psychiatry since its inception in 1947. With a focus on a wide array of topics in neurological and psychiatric health, the journal plays a crucial role in disseminating cutting-edge research and clinical insights that enhance understanding and treatment of neurological disorders. The journal is currently positioned in the Q3 category across various fields, reflecting its role in the academic community, and provides valuable contributions to both the clinical and theoretical aspects of neurology and psychiatry. While it does not offer open access options, NERVENARZT continues to make significant strides in literature with its comprehensive articles and research findings, aimed at researchers, healthcare professionals, and students interested in the latest developments in the neuroscience and mental health landscapes. Operating under rigorous academic standards, it holds respected rankings with Scopus, further underscoring its commitment to impactful scholarship through the years.

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY is a premier academic journal published by Elsevier Science Inc, dedicated to advancing the fields of child and adolescent psychiatry and developmental psychology. With an impressive impact factor ranking it in the Q1 category of both Developmental and Educational Psychology and Psychiatry and Mental Health, this journal serves as a critical platform for researchers and clinicians seeking to address the mental health challenges faced by younger populations. Since its inception in 1962, it has consistently provided a diverse range of scholarly articles that contribute to evidence-based practices in the field, making it an indispensable resource for the global community. The journal is accessible through various academic databases, ensuring that cutting-edge research reaches those who need it most. As we look ahead to its ongoing trajectory from 1987 to 2024, the JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY continues to be at the forefront of mental health research, fostering innovation and collaboration among professionals and students alike.

Welcome to the Australian and New Zealand Journal of Psychiatry, a premier publication dedicated to advancing the field of psychiatric research and mental health practices. Published by SAGE Publications Ltd, this esteemed journal has been a pivotal source of knowledge since its inception in 1967, contributing to the global discourse on psychiatric issues and innovations. With an impressive impact factor positioning it in the Q1 category for both Medicine (miscellaneous) and Psychiatry and Mental Health, it ranks among the top journals with a Scopus rank of #79 out of 567, placing it in the 86th percentile. This journal is committed to fostering interdisciplinary research and clinical practices, providing a platform for high-quality original articles, reviews, and case studies. While it does not currently offer open access options, the insights garnered within its pages are invaluable for researchers, practitioners, and students striving to make impactful contributions to mental health developments. Join our community and explore the dynamic narratives shaping psychiatric science and practice.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

PSYCHIATRIC SERVICES is a leading academic journal published by American Psychiatric Publishing, Inc, dedicated to advancing the understanding and practice of psychiatric care. With a robust ISSN of 1075-2730 and an E-ISSN of 1557-9700, this journal serves as a vital resource for researchers, clinicians, and students in the fields of psychiatry and mental health. Recognized for its high-impact contributions, it holds a prestigious position in the top quartile (Q1) of both the Medicine (miscellaneous) and Psychiatry & Mental Health categories as of 2023, featuring in the Scopus rankings at #164 out of 567, placing it in the 71st percentile. PSYCHIATRIC SERVICES not only provides insights into innovative treatment methodologies and emerging research but also aims to foster a community of knowledge for improving mental healthcare outcomes. While not an Open Access journal, it remains an essential platform for disseminating cutting-edge research from 1995 to 2024 and continues to be an authoritative voice in the dynamic domain of psychiatric services.

British Journal of Psychiatry, published by Cambridge University Press, stands as a pivotal resource in the realm of mental health and psychiatry. With an impressive impact reflected in its Q1 classifications in both Medicine (miscellaneous) and Psychiatry and Mental Health, this esteemed journal ranks 23rd out of 567 in its field according to Scopus, achieving an exceptional 96th percentile. Since its inception in 1963, the journal has continued to push the boundaries of research and discourse, serving as a platform for groundbreaking studies that enhance our understanding of psychiatric conditions and promote effective therapeutic strategies. Though it does not operate with an open-access model, the British Journal of Psychiatry remains an essential publication for researchers, clinicians, and students alike, offering in-depth insights and innovative findings that are crucial for navigating the complexities of mental health.